ANB033 — Topline data
Q4 2026
Top-line Cohort 1 data reaffirmed for Q4 2026Source filing
TRAX biotech catalysts & pipeline
FIRST TRACKS BIOTHERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
ANB101 — Initial data
Q4 2026
Currently evaluating potential development approach informed by clinical and translational evidence, as well as competitor registrational data in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) anticipated in Q4 2026 and early 2027, respectivelySource filing
ANB033 — Topline data
Q1 2027
Cohort 2 (mucosal healing) enhanced to enroll up to 40 patients including those with a broad range of histologic (Vh:Cd ratio ≤ 2.5) and symptom severity to further inform future development; top-line Cohort 2 data anticipated in Q1 2027Source filing
ANB101 — Initial data
early 2027
Currently evaluating potential development approach informed by clinical and translational evidence, as well as competitor registrational data in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) anticipated in Q4 2026 and early 2027, respectivelySource filing
ANB033 — Topline data
Q3 2027
Enrollment ongoing for Phase 1b ANB033 trial in eosinophilic esophagitis (EoE); top-line data anticipated in Q3 2027Source filing